Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria + tetanus + acellular pertussis vaccine (Butantan Foundation)
- Development stage
- Unknown
- Lead developer
- Instituto Butantan
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The diphtheria + tetanus + acellular pertussis (DTaP) vaccine developed by the Butantan Foundation is a combination vaccine designed to provide active immunity against three serious bacterial infections: diphtheria, tetanus, and pertussis (whooping cough). Unlike the whole-cell pertussis vaccine (DTwP), this formulation utilizes acellular pertussis components—specifically purified antigens such as pertussis toxoid and filamentous hemagglutinin—to significantly reduce the risk of local and systemic adverse reactions. The vaccine also contains diphtheria and tetanus toxoids, which are inactivated toxins that stimulate the production of neutralizing antibodies. It is typically administered via intramuscular injection and is used in pediatric populations or as a booster in specific groups to maintain herd immunity and prevent outbreaks.
- Brand names
- Vacina DTPa (Butantan)
- Other names
- Butantan DTaP vaccineVacina Adsorvida Difteria, Tétano e Coqueluche (Acelular)
02
Targets
Diphtheria toxin
Beyond the preview
Go deeper on diphtheria + tetanus + acellular pertussis vaccine (Butantan Foundation).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria + tetanus + acellular pertussis vaccine (Butantan Foundation).